Cost-effectiveness of medical management strategies for nephrolithiasis
- PMID: 15538248
- DOI: 10.1097/01.ju.0000141498.11720.20
Cost-effectiveness of medical management strategies for nephrolithiasis
Abstract
Purpose: We evaluated the cost-effectiveness and stone recurrence rates of common management strategies in stone formers.
Materials and methods: A decision tree model was created to compare the costs of 6 medical treatment strategies, namely dietary measures alone (conservative), empiric drug treatment (empiric), or directed drug therapy based on simple or comprehensive metabolic evaluation. The model assumed cost accrual for evaluation, medications, emergency treatment and surgery for stone recurrence. We determined recurrence rates, medical evaluation sensitivity and the risk reduction of medical treatments from the literature and the costs of surgery, emergency room and medical evaluation at our county hospital. Drug costs were obtained from 2 national pharmacy chains.
Results: In first time stone formers conservative treatment was the least costly strategy and it yielded a stone formation rate of 0.07 stones per patient yearly. In recurrent stone formers conservative treatment was less costly than drug treatments but it was associated with a higher stone recurrence rate (0.3 stones per patient yearly). The remaining drug treatments were more costly than conservative treatment ($885 to 1,187 vs $258 yearly) but they further decreased recurrence rates by 60% to 86%. Modified simple medical evaluation and management (SMEM), that is drug treatment in all patients after simple evaluation) was slightly more costly than empiric treatment and minimally more effective. Comprehensive evaluation and treatment offered no advantage in cost or efficacy over empiric treatment or modified SMEM.
Conclusions: In first time stone formers conservative therapy is cost-effective and efficacious. In recurrent stone formers conservative therapy is unsatisfactory despite low cost because of a high recurrence rate. Modified SMEM and empiric therapy yield the same cost and efficacy as treatments that follow comprehensive evaluation. However, modified SMEM may be advantageous because it offers useful additional medical information.
Comment in
-
Cost-effective management for nephrolithiasis.J Fam Pract. 2005 Feb;54(2):113. J Fam Pract. 2005. PMID: 15689284 No abstract available.
Similar articles
-
International comparison of cost effectiveness of medical management strategies for nephrolithiasis.Urol Res. 2005 Jun;33(3):223-30. doi: 10.1007/s00240-005-0463-9. Epub 2005 May 28. Urol Res. 2005. PMID: 15924256
-
Urolithiasis: Update on Metabolic Evaluation of Stone Formers.ScientificWorldJournal. 2005 Nov 11;5:902-914. doi: 10.1100/tsw.2005.118. eCollection 2005. ScientificWorldJournal. 2005. PMID: 29861685 Free PMC article. Review.
-
When is medical prophylaxis cost-effective for recurrent calcium stones?J Urol. 2002 Sep;168(3):937-40. doi: 10.1016/S0022-5347(05)64546-6. J Urol. 2002. PMID: 12187194
-
Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.BJU Int. 2012 Dec;110(11 Pt C):E1060-7. doi: 10.1111/j.1464-410X.2012.11212.x. Epub 2012 Jun 11. BJU Int. 2012. PMID: 22686216
-
Impact of socioeconomic status in etiology and management of urinary stone disease.Urol Int. 2003;70(4):255-61. doi: 10.1159/000070130. Urol Int. 2003. PMID: 12776701 Review.
Cited by
-
Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial.BMC Nephrol. 2018 Dec 10;19(1):349. doi: 10.1186/s12882-018-1144-6. BMC Nephrol. 2018. PMID: 30526528 Free PMC article. Clinical Trial.
-
Association between chronic pancreatitis and urolithiasis: A population-based cohort study.PLoS One. 2018 Mar 9;13(3):e0194019. doi: 10.1371/journal.pone.0194019. eCollection 2018. PLoS One. 2018. PMID: 29522553 Free PMC article.
-
Approach to the Adult Kidney Stone Former.Clin Rev Bone Miner Metab. 2012 Mar;10(1):38-49. doi: 10.1007/s12018-011-9111-9. Clin Rev Bone Miner Metab. 2012. PMID: 22654574 Free PMC article.
-
Optimal Delivery of Follow-Up Care for the Prevention of Stone Recurrence in Urolithiasis Patients: Improving Outcomes.Res Rep Urol. 2022 Apr 19;14:141-148. doi: 10.2147/RRU.S277498. eCollection 2022. Res Rep Urol. 2022. PMID: 35469244 Free PMC article. Review.
-
Pharmacotherapy of urolithiasis: evidence from clinical trials.Kidney Int. 2011 Feb;79(4):385-92. doi: 10.1038/ki.2010.389. Epub 2010 Oct 6. Kidney Int. 2011. PMID: 20927039 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources